Performance and Safety of the Lotus™ Valve With a FLEXible Delivery System

NCT ID: NCT03043404

Last Updated: 2019-07-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-12-03
• Study Completion Date: 2018-12-10

Brief Summary

To confirm the acute performance and safety of the Lotus™ Valve Flex System for transcatheter aortic valve replacement (TAVR) in symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement.

Detailed Description

This clinical study is a prospective, single-arm study designed to confirm that the acute performance and safety of the Lotus Valve Flex System for TAVR are consistent with the results of the Lotus Valve System in the REPRISE II study, when delivered and deployed in symptomatic subjects who have severe calcific aortic valve stenosis and who are at high risk for surgical aortic valve replacement (SAVR).

Conditions

Aortic Stenosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lotus Valve Flex System

Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System

Group Type: EXPERIMENTAL

Transcatheter aortic valve replacement

Intervention Type: DEVICE

TAVR with Lotus Valve Flex System

Interventions

Transcatheter aortic valve replacement

TAVR with Lotus Valve Flex System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 1. Subject is ≥70 years of age
• 2. Subject has documented calcific native aortic valve stenosis with an initial aortic valve area (AVA) of <1.0 cm2 (or AVA index of <0.6 cm2/m2) and either a mean pressure gradient >40 mm Hg or a jet velocity >4 m/s, as measured by echocardiography
• 3. Subject has a documented aortic annulus size between ≥20 and ≤27 mm based on pre-procedure diagnostic imaging
• 4. Symptomatic aortic valve stenosis with NYHA Functional Class ≥ II
• 5. Subject is considered high risk for surgical valve replacement based on at least one of the following:

1. Society of Thoracic Surgeons (STS) score ≥8%, AND/OR

2. Agreement by the heart team (which must include an in-person evaluation by an experienced cardiac surgeon) that subject is at high operative risk of serious morbidity or mortality with surgical valve replacement

• 6. Heart team (which must include an experienced cardiac surgeon) assessment that the subject is likely to benefit from valve replacement.
• 7. Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent.
• 8. Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits.

Exclusion Criteria

1. Subject has a congenital unicuspid or bicuspid aortic valve.

2. Subject with an acute myocardial infarction within 30 days of the index procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation).

3. Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months, or has any permanent neurologic defect prior to study enrollment.

4. Subject is on dialysis or has serum creatinine level >3.0 mg/dL or 265 µmol/L.

5. Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic ring in any position.

6. Subject has ≥3+ mitral regurgitation, ≥3+ aortic regurgitation or ≥3+ tricuspid regurgitation (i.e., subject cannot have more than moderate mitral, aortic or tricuspid regurgitation).

7. Subject has a need for emergency surgery for any reason.

8. Subject has a history of endocarditis within 12 months of index procedure or evidence of an active systemic infection or sepsis.

9. Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.

10. Subject has Hgb <9 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <1,000 cells/mm3.

11. Subject requires chronic anticoagulation therapy (warfarin) and cannot tolerate concomitant therapy with either aspirin or clopidogrel.

Note: Subjects who require chronic anticoagulation must be able to be treated additionally with either aspirin or clopidogrel. An alternative P2Y12 inhibitor may be prescribed if subject is allergic to or intolerant of clopidogrel.

12. Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3 months, other bleeding diathesis or coagulopathy or will refuse transfusions.

13. Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin, nickel, tantalum, titanium, or polyurethanes.

14. Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrollment.

15. Subject has hypertrophic obstructive cardiomyopathy.

16. Subject has any therapeutic invasive cardiac procedure (including balloon aortic valvuloplasty) within 30 days prior to the index procedure (except for pacemaker implantation which is allowed).

17. Subject has untreated coronary artery disease, which in the opinion of the treating physician is clinically significant and requires revascularization.

18. Subject has documented left ventricular ejection fraction <30%.

19. Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices.

20. Subject has severe peripheral vascular disease (including aneurysm defined as maximal luminal diameter >5 cm or with documented presence of thrombus, marked tortuosity, narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick [>5 mm], protruding or ulcerated atheroma in the aortic arch) or symptomatic carotid or vertebral disease.

21. Femoral artery lumen of <6.0 mm for subjects requiring 23 mm valve size or <6.5 mm for subjects requiring 27 mm valve size, or severe iliofemoral tortuosity or calcification that would prevent safe placement of the introducer sheath.

22. Current problems with substance abuse (e.g., alcohol, etc.).

23. Subject is participating in another investigational drug or device study that has not reached its primary endpoint.

24. Subject has untreated conduction system disorder (e.g., Type II second degree atrioventricular block) that in the opinion of the treating physician is clinically significant and requires a pacemaker implantation.

• Minimum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston Scientific Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ian T Meredith, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Monash

Locations

Prince Charles Hospital

Chermside, Queensland, Australia

Monash Heart

Clayton, Victoria, Australia

Countries

Australia

Other Identifiers

S2321

Identifier Type: -

Identifier Source: org_study_id